Mucosal immunity and tolerance: relevance to vaccine development

被引:184
作者
Czerkinsky, C
Anjuere, F
McGhee, JR
George-Chandy, A
Holmgren, J
Kieny, MP
Fujiyashi, K
Mestecky, JF
Pierrefite-Carle, V
Rask, C
Sun, JB
机构
[1] Fac Med Nice, INSERM, U364, F-06034 Nice, France
[2] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA
[3] Univ Alabama Birmingham, Immunobiol Vaccine Ctr, Birmingham, AL 35294 USA
[4] Univ Gothenburg, Dept Med Microbiol & Immunol, Gothenburg, Sweden
[5] Inst Virol, INSERM, Unit 74, Strasbourg, France
关键词
D O I
10.1111/j.1600-065X.1999.tb01339.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The mucosal immune system of mammals consists of an integrated network of lymphoid cells which work in concert with innate host factors to promote hose defense. Major mucosal effector immune mechanisms include secretory antibodies, largely of immunoglobulin A (IgA) isotype, cytotoxic T-cells, as well as cytokines, chemokines and their receptors. Immunologic unresponsiveness (tolerance) is a key feature of the mucosal immune system, and deliberate vaccination or natural immunization by a mucosal route can effectively induce immune suppression. The diverse compartments located in the aerodigestive and genitourinary tracts and exocrine glands communicate via preferential homing of lymphocytes and antigen-presenting cells. Mucosal administration of antigens may result in the concomitant expression of secretory immunoglobulin A (S-IgA) antibody responses in various mucosal tissues and secretions, and under certain conditions, in the suppression of immune responses. Thus, developing formulations based on efficient delivery of selected antigens/tolerogens, cytokines and adjuvants may impact on the design of future vaccines and of specific immunotherapeutic approaches against diseases associated with untoward immune responses, such as autoimmune disorders, allergic reactions, and tissue-damaging inflammatory reactions triggered by persistent microorganisms.
引用
收藏
页码:197 / 222
页数:26
相关论文
共 266 条
  • [1] DNA vaccination: Transfection and activation of dendritic cells as key events for immunity
    Akbari, O
    Panjwani, N
    Garcia, S
    Tascon, R
    Lowrie, D
    Stockinger, B
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (01) : 169 - 177
  • [2] ALLAN W, 1990, J IMMUNOL, V144, P3980
  • [3] DEVELOPMENT OF IMMUNOLOBULIN LEVELS IN MAN
    ALLANSMITH, M
    MCCLELLAN, BH
    BUTTERWORTH, M
    MALONEY, JR
    [J]. JOURNAL OF PEDIATRICS, 1968, 72 (02) : 276 - +
  • [4] ALLEY CD, 1988, B LYMPHOCYTES HUMAN, P222
  • [5] ROLE OF HOST RESPONSES IN THE RECOVERY OF MICE FROM SENDAI VIRUS-INFECTION
    ANDERSON, MJ
    PATTISON, JR
    CURETON, RJR
    ARGENT, S
    HEATH, RB
    [J]. JOURNAL OF GENERAL VIROLOGY, 1980, 46 (FEB) : 373 - 379
  • [6] Characterization of the expression and immunogenicity of poliovirus replicons that encode simian immunodeficiency virus SIV(mac)239 gag or envelope SU proteins
    Anderson, MJ
    Porter, DC
    Moldoveanu, Z
    Fletcher, TM
    McPherson, S
    Morrow, CD
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 1997, 13 (01) : 53 - 62
  • [7] A plant-based cholera toxin B subunit - insulin fusion protein protects against the development of autoimmune diabetes
    Arakawa, T
    Yu, J
    Chong, DKX
    Hough, J
    Engen, PC
    Langridge, WHR
    [J]. NATURE BIOTECHNOLOGY, 1998, 16 (10) : 934 - 938
  • [8] ARNTZEN CJ, 1996, NEW GENERATION VACCI, P263
  • [9] BACAESTRADA ME, 1995, IMMUNOLOGY, V86, P134
  • [10] Dendritic cells and the control of immunity
    Banchereau, J
    Steinman, RM
    [J]. NATURE, 1998, 392 (6673) : 245 - 252